In the joint program “JOINUS”, the 3 companies will commission work to universities and ventures to reevaluate compound libraries that have already shown pharmacological activity and basic safety in non-clinical studies. More than 50 kinds of mechanisms of action are targeted, and the number of concrete compounds is not disclosed.

Astellas news release, October 11, 2017